Atenolol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317255

CAS#: 29122-68-7

Description: Atenolol is a selective β1 receptor antagonist. It belongs to the group of beta blockers (sometimes written β-blockers), a class of drugs used primarily in cardiovascular diseases. Atenolol was developed as a replacement for propranolol in the treatment of hypertension. It works by slowing down the heart and reducing its workload. Unlike propranolol, atenolol does not pass through the blood–brain barrier to a large extent thus decreasing the incidence of various central nervous system side effect.


Chemical Structure

img
Atenolol
CAS# 29122-68-7

Theoretical Analysis

MedKoo Cat#: 317255
Name: Atenolol
CAS#: 29122-68-7
Chemical Formula: C14H22N2O3
Exact Mass: 266.16304
Molecular Weight: 266.34
Elemental Analysis: C, 63.13; H, 8.33; N, 10.52; O, 18.02

Price and Availability

Size Price Availability Quantity
1.0g USD 150.0 2 Weeks
2.0g USD 250.0 2 Weeks
5.0g USD 450.0 2 Weeks
10.0g USD 750.0 2 Weeks
20.0g USD 1250.0 2 Weeks
Bulk inquiry

Synonym: Atenolol; Tenormin; 29122-68-7; Tenormine; Blokium; Normiten

IUPAC/Chemical Name: 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide

InChi Key: METKIMKYRPQLGS-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

SMILES Code: CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 266.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gong Y, McDonough CW, Beitelshees AL, Rouby NE, Hiltunen TP, O'Connell JR, Padmanabhan S, Langaee TY, Hall K, Schmidt SO, Curry RW Jr, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015 Nov;33(11):2278-85. doi: 10.1097/HJH.0000000000000714. PubMed PMID: 26425837.

2: Yin J, Duan H, Shirasaka Y, Prasad B, Wang J. Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 (hOCT2) and Multidrug and Toxin Extrusion Proteins (hMATEs). Drug Metab Dispos. 2015 Sep 15. pii: dmd.115.066175. [Epub ahead of print] PubMed PMID: 26374172.

3: Di Salvo G, Castaldi B, Gala S, Baldini L, Del Gaizo F, D'Aiello FA, Mormile A, Rea A, Scognamiglio G, Pacileo G, Keating S, Fadel BM, Berrino L, Perna A, Russo MG, Calabrò R. Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation. J Hum Hypertens. 2015 Aug 20. doi: 10.1038/jhh.2015.87. [Epub ahead of print] PubMed PMID: 26290275.

4: Morris KF, Billiot EJ, Billiot FH, Hoffman CB, Gladis AA, Lipkowitz KB, Southerland WM, Fang Y. Molecular Dynamics Simulation and NMR Investigation of the Association of the β-Blockers Atenolol and Propranolol with a Chiral Molecular Micelle. Chem Phys. 2015 Aug 18;457:133-146. PubMed PMID: 26257464; PubMed Central PMCID: PMC4527343.

5: Svan A, Hedeland M, Arvidsson T, Jasper JT, Sedlak DL, Pettersson CE. Rapid chiral separation of atenolol, metoprolol, propranolol and the zwitterionic metoprolol acid using supercritical fluid chromatography-tandem mass spectrometry - Application to wetland microcosms. J Chromatogr A. 2015 Aug 28;1409:251-8. doi: 10.1016/j.chroma.2015.07.075. Epub 2015 Jul 21. PubMed PMID: 26228849.

6: Visser LC, Scansen BA, Brown NV, Schober KE, Bonagura JD. Echocardiographic assessment of right ventricular systolic function in conscious healthy dogs following a single dose of pimobendan versus atenolol. J Vet Cardiol. 2015 Sep;17(3):161-72. doi: 10.1016/j.jvc.2015.04.001. Epub 2015 Jul 26. PubMed PMID: 26213150.

7: Shah JV, Patel DP, Shah PA, Sanyal M, Shrivastav PS. Simultaneous quantification of atenolol and chlorthalidone in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2015 Jun 10. doi: 10.1002/bmc.3537. [Epub ahead of print] PubMed PMID: 26096961.

8: Franken R, Mulder BJ. Aortic disease: Losartan versus atenolol in the Marfan aorta-how to treat? Nat Rev Cardiol. 2015 Aug;12(8):447-8. doi: 10.1038/nrcardio.2015.95. Epub 2015 Jun 16. PubMed PMID: 26076947.

9: Kim NY, Yoo YC, Chun DH, Lee HM, Jung YS, Bai SJ. The Effects of Oral Atenolol or Enalapril Premedication on Blood Loss and Hypotensive Anesthesia in Orthognathic Surgery. Yonsei Med J. 2015 Jul;56(4):1114-21. doi: 10.3349/ymj.2015.56.4.1114. PubMed PMID: 26069137; PubMed Central PMCID: PMC4479842.

10: Meurs KM, Stern JA, Reina-Doreste Y, Maran BA, Chdid L, Lahmers S, Keene BW, Mealey KL. Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker. Pharmacogenet Genomics. 2015 Sep;25(9):427-31. doi: 10.1097/FPC.0000000000000152. PubMed PMID: 26065525.

11: Yousefpour A, Modarress H, Goharpey F, Amjad-Iranagh S. Interaction of PEGylated anti-hypertensive drugs, amlodipine, atenolol and lisinopril with lipid bilayer membrane: A molecular dynamics simulation study. Biochim Biophys Acta. 2015 Aug;1848(8):1687-98. doi: 10.1016/j.bbamem.2015.04.016. Epub 2015 May 8. PubMed PMID: 25960186.

12: Lamie NT. Simultaneous determination of binary mixture of amlodipine besylate and atenolol based on dual wavelengths. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Oct 5;149:201-7. doi: 10.1016/j.saa.2015.04.077. Epub 2015 Apr 30. PubMed PMID: 25958126.

13: Denardo SJ, Gong Y, Cooper-DeHoff RM, Farsang C, Keltai M, Szirmai L, Messerli FH, Bavry AA, Handberg EM, Mancia G, Pepine CJ. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy. PLoS One. 2015 Apr 2;10(4):e0122726. doi: 10.1371/journal.pone.0122726. eCollection 2015. PubMed PMID: 25835002; PubMed Central PMCID: PMC4383326.

14: Aparicio LS, Alfie J, Barochiner J, Cuffaro PE, Giunta DH, Elizondo CM, Tortella JJ, Morales MS, Rada MA, Waisman GD. Comparison of atenolol versus bisoprolol with noninvasive hemodynamic and pulse wave assessment. J Am Soc Hypertens. 2015 May;9(5):390-6. doi: 10.1016/j.jash.2015.02.013. Epub 2015 Feb 23. PubMed PMID: 25816713.

15: Bhatt AB, Buck JS, Zuflacht JP, Milian J, Kadivar S, Gauvreau K, Singh MN, Creager MA. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vasc Med. 2015 Aug;20(4):317-25. doi: 10.1177/1358863X15569868. Epub 2015 Mar 20. Review. PubMed PMID: 25795452.

16: Güleç A, Albayrak H, Kayapinar O, Albayrak S. Pityriasis rosea-like adverse reaction to atenolol. Hum Exp Toxicol. 2015 Mar 18. pii: 0960327115580220. [Epub ahead of print] PubMed PMID: 25791321.

17: Georgianos PI, Agarwal R. Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis. Clin J Am Soc Nephrol. 2015 Apr 7;10(4):639-45. doi: 10.2215/CJN.09981014. Epub 2015 Mar 17. PubMed PMID: 25784174; PubMed Central PMCID: PMC4386263.

18: Cheng B, Li L, Zhou R, Nie G, Zhang H. [Enantioseparation and determination of atenolol enantiomers in tables on a β-cyclodextrin-based chiral stationary phase by high performance liquid chromatography]. Se Pu. 2014 Nov;32(11):1219-24. Chinese. PubMed PMID: 25771541.

19: Sarfraz RM, Khan HU, Mahmood A, Ahmad M, Maheen S, Sher M. Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin. Indian J Pharm Sci. 2015 Jan-Feb;77(1):83-90. PubMed PMID: 25767322; PubMed Central PMCID: PMC4355887.

20: Read MI, Harrison JC, Kerr DS, Sammut IA. Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus. Br J Pharmacol. 2015 Oct;172(19):4626-38. doi: 10.1111/bph.13132. Epub 2015 Aug 24. PubMed PMID: 25765931; PubMed Central PMCID: PMC4594268.